Home › Trial NCT05017025
Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer
- Trial IDNCT05017025
- StatusCompleted
- PhasePhase 1/2
- Study typeInterventional
- SponsorM.D. Anderson Cancer Center
- Enrollment32
- Start date2022-02-17
- ConditionsAdvanced Lung Non-Squamous Non-Small Cell Carcinoma · Metastatic Lung Non-Squamous Non-Small Cell Carcinoma · Stage III Lung Cancer AJCC v8 · Stage IIIA Lung Cancer AJCC v8 · Stage IIIB Lung Cancer AJCC v8 · Stage IIIC Lung Cancer AJCC v8
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.